# US 2024/0199620 A1 · Chemokine receptor modulators and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199620 A1
- Document ID: US20240199620A1
- Status: Published application
- Kind: A1
- Application number: 18/389,182
- Filed: 2023-11-13
- Published: 2024-06-20
- Earliest claimed: 2016-07-29
- Assignees: Rapt Therapeutics, Inc.
- Applicants: Rapt Therapeutics, Inc.
- Inventors: Hilary Plake Beck; Berenger Biannic; Minna Hue Thanh Bui; Dennis X. Hu; John Michael Ketcham; Jay Patrick Powers; Maureen Kay Reilly; Omar Robles-Resendiz; Hunter Paul Shunatona; James Ross Walker; David Juergen Wustrow; Ashkaan Younai; Mikhail Zibinsky; Jeffrey J. Jackson
- Web page: https://patentgrep.com/patent/US20240199620A1

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/235: having an aromatic ring attached to a carboxyl group
- A61K 31/42: Oxazoles
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/4706: 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/7135: Compounds containing heavy metals
- A61K 31/728: Hyaluronic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of CCR4 activity.

## Claims

### Claim at position 1

-68. (canceled)

### Claim 69

A compound having a structural formula:
or a pharmaceutically acceptable salt thereof, wherein:
z1 is 3;
R3 is halogen or —OR3A; wherein R3A is hydrogen; and
R7 is substituted or unsubstituted alkyl.

### Claim 70 (depends on 69)

The compound of claim 69, wherein R7 is a substituted alkyl.

### Claim 71 (depends on 70)

The compound of claim 70, wherein R7 is a substituted C1-C4 alkyl.

### Claim 72 (depends on 71)

The compound of claim 71, wherein R7 is —CH2CH2OH.

### Claim 73 (depends on 69, 70, 71, 72)

A method of treating cancer mediated by C—C chemokine receptor type 4 (CCR4) in a subject in need thereof, said method comprising contacting the CCR4 in said subject with the compound of any one of claims 69 to 72.

### Claim 74 (depends on 73)

The method of claim 73, wherein the cancer is non-small cell lung cancer, head and neck squamous cell carcinoma, gastric cancer or lymphoma.

### Claim 75 (depends on 73)

The method of claim 73, further comprising administering a second therapeutic agent.

### Claim 76 (depends on 75)

The method of claim 75, wherein the second therapeutic agent is a chemotherapeutic or anticancer agent.

### Claim 77 (depends on 76)

The method of claim 76, wherein the chemotherapeutic agent or anticancer agent is an antiproliferative/antineoplastic drug, an antimetabolite, an antitumour antibiotic, an antimitotic agent, a topoisomerase inhibitor, a cytostatic agent, an oestrogen receptor down regulator, an antiandrogen, a LHRH antagonist or LHRH agonist, a progestogen, an aromatase inhibitor, an inhibitor of 5.alpha.-reductase, an agent which inhibits cancer cell invasion, an inhibitor of growth factor function, a farnesyl transferase inhibitor, a tyrosine kinase inhibitor, a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family, an inhibitor of the platelet-derived growth factor family, an inhibitor of the hepatocyte growth factor family; an antiangiogenic agent, a vascular damaging agent, an agent used in antisense therapy, an anti-ras antisense, an agent used in a gene therapy, an immunotherapeutic agent, or an antibody.

### Claim 78 (depends on 76)

The method of claim 76, wherein the chemotherapeutic agent or anticancer agent is an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4 or an agonistic antibody of CD137 (4-1BB).

### Claim 79 (depends on 76)

The method of claim 76, wherein the chemotherapeutic agent or anticancer agent is pembrolizumab.
